Gavreto

GAVRETO- pralsetinib capsule
Genentech, Inc.

1 INDICATIONS AND USAGE

1.1 Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

GAVRETO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

1.2 RET Fusion-Positive Thyroid Cancer

GAVRETO is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14.2)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

2 DOSAGE AND ADMINISTRATION

2.1 Patient Selection

Select patients for treatment with GAVRETO based on the presence of a RET gene fusion (NSCLC or thyroid cancer) [see Clinical Studies (14)].

Information on FDA-approved tests for RET gene fusion (NSCLC) is available at http://www.fda.gov/CompanionDiagnostics.

An FDA-approved test for the detection of RET gene fusion (thyroid cancer) is not currently available.

2.2 Recommended Dosage

The recommended dosage of GAVRETO is 400 mg orally once daily on an empty stomach (no food intake for at least 2 hours before and at least 1 hour after taking GAVRETO) [see Clinical Pharmacology (12.3)]. Continue treatment until disease progression or until unacceptable toxicity.

If a dose of GAVRETO is missed, it can be taken as soon as possible on the same day. Resume the regular daily dose schedule for GAVRETO the next day.

Do not take an additional dose if vomiting occurs after GAVRETO but continue with the next dose as scheduled.

2.3 Dosage Modifications for Adverse Reactions

The recommended dose reductions and dosage modifications for adverse reactions are provided in Table 1 and Table 2.

Table 1: Recommended Dose Reductions for GAVRETO for Adverse Reactions
Dose Reduction Recommended Dosage
First 300 mg once daily
Second 200 mg once daily
Third 100 mg once daily

Permanently discontinue GAVRETO in patients who are unable to tolerate 100 mg taken orally once daily.

The recommended dosage modifications for adverse reactions are provided in Table 2.

Table 2: Recommended Dosage Modifications for GAVRETO for Adverse Reactions
Adverse Reaction Severity * Dosage Modification
*
Adverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03
ILD/Pneumonitis [see Warnings and Precautions (5.1)] Grade 1 or 2 Withhold GAVRETO until resolution. Resume by reducing the dose as shown in Table 1.
Permanently discontinue GAVRETO for recurrent ILD/pneumonitis.
Grade 3 or 4 Permanently discontinue for confirmed ILD/pneumonitis.
Hypertension [see Warnings and Precautions (5.2)] Grade 3 Withhold GAVRETO for Grade 3 hypertension that persists despite optimal antihypertensive therapy. Resume at a reduced dose when hypertension is controlled.
Grade 4 Discontinue GAVRETO.
Hepatotoxicity [see Warnings and Precautions (5.3)] Grade 3 or 4 Withhold GAVRETO and monitor AST/ALT once weekly until resolution to Grade 1 or baseline.
Resume at reduced dose (Table 1).
For recurrent events at Grade 3 or higher, discontinue GAVRETO.
Hemorrhagic Events [see Warnings and Precautions (5.4)] Grade 3 or 4 Withhold GAVRETO until recovery to baseline or Grade 0 or 1.
Discontinue GAVRETO for severe or life-threatening hemorrhagic events.
Other Adverse Reactions [see Adverse Reactions (6.1)] Grade 3 or 4 Withhold GAVRETO until improvement to ≤ Grade 2. Resume at reduced dose (Table 1).
Permanently discontinue for recurrent Grade 4 adverse reactions.

2.4 Dose Modification for Use with CYP3A and/or P-glycoprotein (P-gp) Inhibitors

Avoid coadministration of GAVRETO with any of the following:

  • Strong CYP3A inhibitors
  • Moderate CYP3A inhibitors
  • P-gp inhibitors
  • Combined P-gp and strong CYP3A inhibitors
  • Combined P-gp and moderate CYP3A inhibitors

If coadministration with any of the above inhibitors cannot be avoided, reduce the current dose of GAVRETO as recommended in Table 3. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, resume GAVRETO at the dose taken prior to initiating the inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].

Table 3: Recommended Dosage Modifications for GAVRETO for Coadministration with CYP3A and/or P-gp Inhibitors
Current GAVRETO Dosage Recommended GAVRETO Dosage when Coadministered with:
Combined P-gp and Strong CYP3A Inhibitors
  • Strong CYP3A Inhibitors;
  • Moderate CYP3A Inhibitors;
  • P-gp Inhibitors;
  • Combined P-gp and Moderate CYP3A Inhibitors
400 mg orally once daily 200 mg orally once daily 300 mg orally once daily
300 mg orally once daily 200 mg orally once daily 200 mg orally once daily
200 mg orally once daily 100 mg orally once daily 100 mg orally once daily

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2024. All Rights Reserved.